Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Authors
Keywords
-
Journal
JAMA Cardiology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2022-06-01
DOI
10.1001/jamacardio.2022.1292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
- (2021) Jan Steffel et al. EUROPACE
- Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
- (2021) An S. De Vriese et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication
- (2021) Jordan K. Schaefer et al. JAMA Internal Medicine
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
- (2021) John W. Eikelboom et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
- (2021) Behnood Bikdeli et al. THROMBOSIS AND HAEMOSTASIS
- Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
- (2021) Jun Qian et al. Frontiers in Pharmacology
- Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients
- (2021) Bo Zhou et al. Frontiers in Cardiovascular Medicine
- Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer
- (2021) Steven Deitelzweig et al. JACC: CardioOncology
- Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry
- (2021) Agnieszka Kotalczyk et al. International Journal of Stroke
- Select Drug-Drug Interactions With Direct Oral Anticoagulants
- (2020) Barbara S. Wiggins et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban in Peripheral Artery Disease after Revascularization
- (2020) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
- (2020) Gordon F. Tomaselli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure
- (2020) Joseph R. Shaw et al. Blood Advances
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
- (2020) Alan John Camm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
- (2020) Ken Okumura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism
- (2020) Javier Trujillo-Santos et al. THROMBOSIS RESEARCH
- American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
- (2020) Thomas L. Ortel et al. Blood Advances
- Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
- (2020) Helio P. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on Guidelines for the Management of Cancer‐Associated Thrombosis
- (2020) Michael B. Streiff et al. ONCOLOGIST
- Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach
- (2020) Taylor Dawson et al. Journal of the American Heart Association
- 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease
- (2020) Dharam J. Kumbhani et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function
- (2019) So-Ryoung Lee et al. STROKE
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
- (2019) Alok A. Khorana et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- (2019) Renato D. Lopes et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
- (2019) Craig T. January et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
- (2019) Stefan H Hohnloser et al. EUROPEAN HEART JOURNAL
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
- (2019) Stavros V Konstantinides et al. EUROPEAN HEART JOURNAL
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
- (2019) Pascal Vranckx et al. LANCET
- Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
- (2019) Satoshi Yasuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
- (2019) James D. Douketis et al. JAMA Internal Medicine
- A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
- (2019) George D. Dangas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Renal Function Estimation Formulae for Dosing Direct Oral Anticoagulants in Patients with Atrial Fibrillation
- (2019) Kwang-No Lee et al. Journal of Clinical Medicine
- Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery
- (2018) Michelle M. Graham et al. ANNALS OF INTERNAL MEDICINE
- Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis
- (2018) Bruria Hirsh Raccah et al. ANNALS OF PHARMACOTHERAPY
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
- (2018) Annie M. Young et al. JOURNAL OF CLINICAL ONCOLOGY
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- (2018) Gary E. Raskob et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
- (2018) Robert G. Hart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE)
- (2018) Behnood Bikdeli et al. THROMBOSIS AND HAEMOSTASIS
- Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
- (2018) Benjamin A. Steinberg et al. Journal of the American Heart Association
- Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation
- (2018) Yi-Cheng Lin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
- (2018) Alex C. Spyropoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
- (2018) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
- (2018) Marc Carrier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
- (2017) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
- (2017) Jeffrey I. Weitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens
- (2017) Javier Trujillo-Santos et al. THROMBOSIS AND HAEMOSTASIS
- Antithrombotic Therapy for VTE Disease
- (2016) Clive Kearon et al. CHEST
- When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
- (2016) J. H. Levy et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
- (2016) C. Michael Gibson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
- (2015) Giuseppe Lippi et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
- (2015) Dolly A. Parasrampuria et al. CLINICAL PHARMACOKINETICS
- Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
- (2015) Gregory Y.H. Lip et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
- (2013) Sam Schulman et al. CIRCULATION
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
- (2013) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
- (2013) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
- (2013) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Apixaban for the Treatment of Acute Venous Thromboembolism
- (2013) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation
- (2012) Masatsugu Hori et al. CIRCULATION JOURNAL
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban for Extended Treatment of Venous Thromboembolism
- (2012) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban in Patients with Atrial Fibrillation
- (2011) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
- (2011) Ola Dahl et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
- (2010) Michael Rud Lassen et al. LANCET
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
- (2010) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
- (2009) Joachim Stangier et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
- (2009) Alexander GG Turpie et al. LANCET
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- (2009) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
- (2008) JOURNAL OF ARTHROPLASTY
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
- (2008) Ajay K Kakkar et al. LANCET
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
- (2008) Bengt I. Eriksson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
- (2008) Michael R. Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search